Societal CDMO (NASDAQ:SCTL – Get Rating) is one of 938 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Societal CDMO to similar companies based on the strength of its analyst recommendations, profitability, dividends, risk, valuation, institutional ownership and earnings.
Insider & Institutional Ownership
59.3% of Societal CDMO shares are held by institutional investors. Comparatively, 45.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 7.8% of Societal CDMO shares are held by company insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Societal CDMO has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Societal CDMO’s peers have a beta of 1.12, meaning that their average stock price is 12% more volatile than the S&P 500.
This is a breakdown of current recommendations for Societal CDMO and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Societal CDMO Competitors||6281||20841||43107||862||2.54|
As a group, “Pharmaceutical preparations” companies have a potential upside of 132.71%. Given Societal CDMO’s peers higher probable upside, analysts clearly believe Societal CDMO has less favorable growth aspects than its peers.
Valuation and Earnings
This table compares Societal CDMO and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Societal CDMO||$75.36 million||-$11.37 million||-4.23|
|Societal CDMO Competitors||$1.86 billion||$252.18 million||-2.22|
Societal CDMO’s peers have higher revenue and earnings than Societal CDMO. Societal CDMO is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Societal CDMO and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Societal CDMO Competitors||-4,290.74%||-171.93%||-7.00%|
Societal CDMO peers beat Societal CDMO on 5 of the 9 factors compared.
Societal CDMO Company Profile (Get Rating)
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Receive News & Ratings for Societal CDMO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Societal CDMO and related companies with MarketBeat.com's FREE daily email newsletter.